Page 1

Half - Year Report 2026 January - June ASCELIA PHARMA Advancing Orphan Oncology Focus on the Path Forward for Orviglance® KEY EVENTS IN Q2 2026 ■ Ascelia Pharma completed a directed share issue of SEK 20 million before transaction costs Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 " Our focus now is to work constructively with the FDA to identify the most efficient path for- ward and advance Orviglance toward approval . " KEY RATIOS GROUP ■ Orviglance data presented at the Annual Radiology Congress ESGAR 2026 ◉ Orviglance IP Portfolio expanded with new patent filing KEY EVENTS AFTER THE PERIOD ◉ Ascelia Pharma receives a Complete Response Letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for Orviglance ■ Ascelia Pharma announces CFO Anton Hansson's departure , alongside measures to reduce the cost base ◉ Ascelia Pharma announces that FDA has scheduled a Type A meeting on September 9 , 2026 Q2 ( Apr - Jun ) 2026 2025 2026 H1 ( Jan - Jun ) 2025 OPERATING RESULT ( SEKM ) -12.1 -23.0 -28.6 -43.3 EARNINGS PER SHARE ( SEK ) -0.09 -0.20 -0.22 -0.43 CASH FLOW FROM OPERATIONS ( SEKm ) -14.0 -18.0 -29.8 -34.9 LIQUID ASSETS ( SEKM ) 38.0 60.4 38.0 60.4